A Clinical Study to Evaluate the Immunogenicity and Safety of Pandemic Influenza Vaccine, AdimFlu-W (H5N1), in Healthy Adults

Adimmune Corporation1 site in 1 country39 target enrollmentJuly 10, 2012

ConditionsPandemic Influenza

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Pandemic Influenza
Sponsor: Adimmune Corporation
Enrollment: 39
Locations: 1
Primary Endpoint: Immunogenicity Endpoint: hemagglutination inhibition (HAI) titer and microneutralization (MN) titer
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The objectives of this single arm study are to evaluate the immune response and safety profiles of two injections of an inactivated whole-virion vaccine containing aluminum hydroxide adjuvant, AdimFlu-W (H5N1), against influenza A (H5N1) in healthy adults.

Registry

clinicaltrials.gov

Start Date

July 10, 2012

End Date

June 2013

Last Updated

7 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Adimmune Corporation

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•A male or non-pregnant female (as indicated by a negative urine pregnancy test immediately on the day prior to first vaccine administration) between 20 to 60 years of age at the time of the first vaccination. Women of childbearing potential agree to practice highly effective birth control throughout the study (from Screening to Month 3).
•Subjects are free of obvious health problems as judged by investigator (established by medical history and physical examination) before entering the study.
•Subject is physically and mentally capable of participating in the study and willing to adhere to study procedures to complete all elements of the study diary.
•Subjects provide signed informed consent after receiving a detailed explanation of the study protocol prior to any study procedures.

Exclusion Criteria

•Medical history of physician-confirmed infection with an H5N1 virus or a history of vaccination with an H5N1 influenza vaccine.
•Subject is at high risk of contracting H5N1 influenza infection (e.g. poultry workers).
•Has received any other licensed vaccines within 2 weeks for inactivated vaccines or 4 weeks for live vaccines prior to enrollment in this study.
•Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
•Subject has used oral or parenteral steroids, high-dose inhaled steroids (\>800 mcg/day of beclomethasone dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs within 30 days preceding the first dose of study vaccine.
•Subject has received a blood transfusion or immunoglobulins within 90 days prior to first dose of study vaccine, or planned administration of any blood products during the study period.
•Subject has a known allergy to eggs or other components of the study vaccine.
•Subject has a history of severe allergic reactions or anaphylaxis.
•Subject has a history of Guillain-Barré Syndrome.
•Subject has an acute illness or temperature greater than 38.0 degrees Celsius by any method within 3 days prior to each vaccination.

Outcomes

Primary Outcomes

Immunogenicity Endpoint: hemagglutination inhibition (HAI) titer and microneutralization (MN) titer

Time Frame: At Day 43 (21 days after the second dose).

The primary immune response endpoint is to evaluate the seroconversion rate (SCR) in terms of HAI assays at Day 43 (21 days after the second dose).The secondary HAI endpoints are defined as following: 1. SCR for the first vaccination, at Day 22. 2. Seroprotection rates (SPR) for each vaccination, at Day 22 and 43. 3. The geometric mean fold rise (GMFR) for each vaccination, at Day 22 and 43. The supportive immunogenicity endpoints of MN antibodies are SCRs, SPRs and GMFRs at Day 22 and 43.

Secondary Outcomes

The secondary objective is to evaluate the safety and tolerability profiles including the presence or absence of the pre-specified reactogenicity events and other serious/non-serious adverse events after vaccination.(At 4 weeks after two doses of study vaccine, 4 weeks apart. Reactogenicity will be recorded for 7 days after each vaccination.)